MEDI-6012
N/A
Report date: 2026/01/18 20:00:10
Base Information
Drug NameMEDI-6012
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[4]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[11]
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcColumbia UniversityMedimmune Llc
Active IndicationsN/A
Inactive Indications +[4]
Other Information
ATC CodeN/A
Related LinksN/A